AFC
AZN icon

Ares Financial Consulting’s AstraZeneca AZN Stock Holding History

Ares Financial Consulting’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.2K Buy
+486
New +$91.4K 0.07% 156
2026
Q1 		– Sell
-10
Closed -$1.84K – 1070
2025
Q4 		$1.84K Buy
+10
New +$1.75K ﹤0.01% 673

Other funds holding AZN

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Ares Financial Consulting's AZN Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in AstraZeneca (AZN) in Q2 2026: 486 shares worth $92.2K. The stake represents 0.07% of the portfolio and ranks #156 among its holdings. This is a return to the name: Ares Financial Consulting previously reported a position in AZN as recently as Q4 2025.

Ares Financial Consulting first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 797 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Ares Financial Consulting held 486 shares of AstraZeneca worth $92.2K as of Q2 2026.
  • AstraZeneca was a new Ares Financial Consulting position in Q2 2026.
  • AstraZeneca made up 0.07% of Ares Financial Consulting's portfolio in Q2 2026, its #156 holding.
  • Ares Financial Consulting first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
  • 797 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.